Wellcome Leap logo
Program

R3 Global

Helps Global for continuous-flow RNA medicine manufacturing at scale for innovation and strategic advancement.

Wellcome LeapCooperative agreement

R3 Global is a $60M Wellcome Leap program co-funded with CEPI. It extends the earlier R3 effort, which began in 2021, into a scaling phase that is building a distributed network of biofoundries across multiple countries. The program is active and currently in the next phase of scaling.

The technical center is continuous-flow RNA medicine manufacturing at scale, with the larger ambition of produci

BiotechAdvanced ManufacturingSynthetic Biology

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.

Last verified: 1 Jun 2026Source: wellcomeleap.org